Answers are grounded in this paper and cite their sources.
Multiple sclerosis (MS) is a chronic autoimmune, inflammatory, demyelinating disease of the central nervous system, characterized by progressive neurodegeneration and disability. Current disease-modifying therapies primarily target peripheral immune cells and show limited efficacy in halting relapse-independent long-term progression and the resulting neurodegeneration. The type 5 metabotropic glutamate receptor (mGluR5) has emerged as a promising therapeutic target due to its role in regulating neuroinflammation and cell survival. This study evaluated the therapeutic efficacy of VU0409551, a selective mGluR5 positive allosteric modulator (PAM), in the experimental autoimmune encephalomyelitis (EAE) mouse model, the most widely studied animal model of MS. Daily treatment with VU0409551 (10 mg/kg, intraperitoneally) significantly attenuated clinical disease severity and prevented characteristic body weight loss. Proteomic analyses revealed that VU0409551 treatment attenuated molecular signatures associated with immune responses. During remission, VU0409551 ameliorated EAE-associated anxiety-like behavior and attenuated persistent cortical neuroinflammatory alterations, including astrogliosis, microglial accumulation, and increased TNF expression. Notably, treatment also reduced signatures associated with astrocyte and oligodendrocyte reactivity, including C3, C4b, Serpina3n, and H2-D1. These findings demonstrate that VU0409551 exerts robust therapeutic effects, positioning it as a promising and novel disease-modifying candidate for MS.
No takes yet. Share an insight, caveat, or question.
Goulart et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: